Bioengineering hemophilia A–specific microvascular grafts for delivery of full-length factor VIII into the bloodstream

Hemophilia A (HA) is a bleeding disorder caused by mutations in the F8 gene encoding coagulation factor VIII (FVIII). Current treatments are based on regular infusions of FVIII concentrates throughout a patient’s life. Alternatively, viral gene therapies that directly deliver F8 in vivo have shown p...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Neumeyer, Joseph, Lin, Ruei-Zeng, Wang, Kai, Hong, Xuechong, Hua, Tien, Croteau, Stacy E., Neufeld, Ellis J., Melero-Martin, Juan M.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2019
Sujets:
Gene Therapy
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6929393/
https://ncbi.nlm.nih.gov/pubmed/31851760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000848
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires